First Therapeutic Vaccine for Advanced Lung Cancer Registered in the World

Between 1980 and 2008, mortality rates from lung cancer among women has doubled. Every year sees an increase of 1.7 percent, while among men the rate is reduced by 2 percent. Today, 28.6% of women aged 18-64 years, and it is estimated that 7.6 million people died only in 2008 due to lung cancer, a number that is expected to increase to eleven million in the 2030th

It is quite possible that two of the biggest concerns associated with the health of citizens expressed in any country in the world as AIDS and cancer. Although there are other diseases that are less "reporters" and charge a huge amount of victims each year, especially in the tropics, it is true that getting a vaccine effective against cancer or AIDS among the main goals of laboratories around the world.

Fortunately, the fight against lung cancer has won a new step: it is a therapeutic vaccine rather than preventative, developed by recombinant technology of advanced lung cancer, CimaVax-EGF, was created in Cuba, scientists at the Center of Molecular Immunology, Havana.

This Cuban medicine has been prepared after 15 years of research and is currently implemented in 65 health centers in Cuba, and have taken measures necessary to register in Brazil, Argentina, Colombia and several other countries.

According to Cuban experts, the drug can prevent the disease, but for control of advanced cancer of the production of antibodies against proteins that trigger the process of uncontrolled cell proliferation.

consists of a therapeutic tool that is part of the area of immunotherapy, in which it is intended that the patient's immune system triggers an effective response to control tumor growth.

The vaccine consists of the protein epidermal growth factor and P-64 K of membranes, produced by recombinant sredstvima.Cjepivo been successfully applied to more than 1000 patients in Cuba, where his health record was held in June 2008.

The result is that the vaccine provides a survival time of patients, but does not prevent or cure lung cancer.
Experts have described the vaccine as "very promising" that will soon come to another will be tested in China and will open doors in Asia. Also expects the next clinical trial in countries such as Australia, Thailand, Malaysia and the UK.

According to Gonzalez (proyect leader) still work with the principle of vaccines intended to be used in development compared to other cancer therapies such as prostate, uterine and breast cancer.